COVID-19 vaccine trials in Africa
On Aug 17, 2020, screening began for participants to enrol in the mid-stage study of an experimental COVID-19 vaccine by Novavax, a US drug developer of next-generation vaccines for serious infectious diseases, at Witwatersrand University (Wits) in Johannesburg, South Africa. A US$15 million grant t...
- Autores:
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13208
- Acceso en línea:
- https://www.sciencedirect.com/science/article/pii/S221326002030401X
http://hdl.handle.net/20.500.12010/13208
https://doi.org/10.1016/S2213-2600(20)30401-X
- Palabra clave:
- COVID-19
Vaccines
COVID-19
- Rights
- License
- Acceso restringido
| Summary: | On Aug 17, 2020, screening began for participants to enrol in the mid-stage study of an experimental COVID-19 vaccine by Novavax, a US drug developer of next-generation vaccines for serious infectious diseases, at Witwatersrand University (Wits) in Johannesburg, South Africa. A US$15 million grant towards the trial was awarded to Novavax by the Bill & Melinda Gates Foundation. 2665 healthy adults and nearly 240 medically stable, HIV-positive adults will be enrolled. |
|---|